Immune-modified exosome vaccine loaded with liver cancer epitope peptides induces potent and specific antitumor immunity - PubMed
6 hours ago
- #PD-L1-blockade
- #liver-cancer-immunotherapy
- #exosome-vaccine
- A multifunctional dendritic cell-derived exosome vaccine (DEXAGNP) was developed for liver cancer, combining epitope presentation, innate immune activation, and PD-L1 blockade.
- DEXAGNP loaded with HLA-A*02:01-restricted peptides (e.g., hAFP158-166, hGPC3144-152) and used anti-PD-L1 antibodies to block immunosuppression, enhancing antigen-specific CD8+ T-cell responses.
- In vitro and in vivo studies showed DEXAGNP induced cytotoxicity against liver cancer cells, suppressed tumor growth in mouse models, and promoted memory-like T-cell responses in prophylactic settings.
- The vaccine demonstrated efficacy in immunocompetent subcutaneous, humanized xenograft, and orthotopic hepatocellular carcinoma models, as well as ex vivo with clinical HCC specimens.
- DEXAGNP is presented as a modular platform for next-generation exosome-based cancer vaccines, offering a practical blueprint for immunotherapy in liver cancer.